Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Sierra Oncology, Inc. (SRRA) Create: Alert

All | News | Filings
Date FiledTypeDescription
05/06/2022 8-K Quarterly results
Docs: "Sierra Oncology Reports First Quarter 2022 Results"
11/05/2021 8-K Quarterly results
Docs: "Letter re: Registration Statement on Form S-3",
"Sierra Oncology Reports Third Quarter 2021 Results – MOMENTUM study on track for topline data read-out by February 2022 – – Global in-licensing deal expands myelofibrosis pipeline and provides options for combination studies in"
08/05/2021 8-K Quarterly results
05/07/2021 8-K Quarterly results
11/05/2020 8-K Quarterly results
Docs: "Sierra Oncology Reports Third Quarter 2020 Results - MOMENTUM Phase 3 clinical trial enrollment on track; top-line data anticipated in H1 2022 -"
08/06/2020 8-K Quarterly results
05/07/2020 8-K Quarterly results
08/08/2019 8-K Quarterly results
05/08/2019 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : May 8, 2019 SIERRA ONCOLOGY, INC. Delaware 001- 37490 20-0138994 c/o 2150 - 885 West Georgia Street Vancouver, British Columbia, Canada V6C 3E8 558-6536 N/A Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant...",
"Sierra Oncology Reports First Quarter 2019 Results - Momelotinib regulatory pathway clarity anticipated in Q2 2019 - - SRA737 Phase 1/2 preliminary clinical data anticipated at the 2019 ASCO Annual Meeting - Vancouver - May 8, 2019. Sierra Oncology, Inc. , a clinical stage drug development company focused on advancing targeted therapeutics for the treatment of patients with unmet needs in hematology and oncology, today reported its financial and operational results for the first quarter ended March 31, 2019. “During the first quarter, we advanced productive dialogues with regulators in the United States and Europe toward determining the registration path for momelotinib, our Phase 3 drug candidate with a potentially differentiated profile for the treatment of myelofibrosis. These discussio..."
11/08/2018 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : November 8, 2018 SIERRA ONCOLOGY, INC. Delaware 001- 37490 20-0138994 c/o 2150 - 885 West Georgia Street Vancouver, British Columbia, Canada V6C 3E8 558-6536 N/A Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pur...",
"Sierra Oncology Reports Third Quarter Results - Momelotinib regulatory pathway clarity anticipated in H1 2019 - - SRA737 Monotherapy and LDG Combination trial preliminary data anticipated in H1 2019 - VANCOUVER, November 8, 2018—Sierra Oncology, Inc. , a clinical stage drug development company focused on advancing targeted therapeutics for the treatment of patients with significant unmet needs in hematology and oncology, today reported its financial and operational results for the third quarter ended September 30, 2018. “During the third quarter, we fundamentally transformed Sierra with the addition of momelotinib to our portfolio, a differentiated, demonstrably active and well-tolerated Phase 3 drug candidate for the treatment of myelofibrosis. We are currently preparing for discussions w..."
08/09/2018 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : August 9, 2018 SIERRA ONCOLOGY, INC. Delaware 001- 37490 20-0138994 c/o 2150 - 885 West Georgia Street Vancouver, British Columbia, Canada V6C 3E8 558-6536 N/A Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursu...",
"Sierra Oncology Reports Second Quarter Results - SRA737 Monotherapy trial prioritized for ovarian cancer; targeting enrollment of 65 patients with preliminary data anticipated in H1 2019 - - SRA737 LDG Combination trial to be amended and prioritized to include 20 patient ovarian cancer cohort - - SRA737 + PARPi combination trial expected to be initiated in Q4 2018 - - SRA141 IND expected to be submitted in H2 2018 - - $125.4 million cash expected to fund programs through approximately mid-2020 - VANCOUVER, August 9, 2018 - Sierra Oncology, Inc. , a clinical stage drug development company focused on advancing next generation DNA Damage Response therapeutics for the treatment of patients with cancer, today reported its financial and operational results for the second quarter ended June 30, 2..."
05/10/2018 8-K Quarterly results
Docs: "FORM 8-K",
"Sierra Oncology Reports First Quarter Results"
11/08/2017 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : November 8, 2017 SIERRA ONCOLOGY, INC. Delaware 001- 37490 20-0138994 2150 - 885 West Georgia Street Vancouver, British Columbia, Canada V6C 3E8 558-6536 N/A Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuan...",
"Sierra Oncology Reports Third Quarter Results - Chk1 inhibitor SRA737 Monotherapy trial expanded to eight leading centers across the UK - - On track to provide planned SRA737 Program Update in February 2018 - - $107.8 million cash expected to fund current operating plans through approximately mid-2019 - Vancouver - Nov 8, 2017. Sierra Oncology, Inc. , a clinical stage drug development company focused on advancing next generation DNA Damage Response therapeutics for the treatment of patients with cancer, today reported its financial and operational results for the third quarter ended September 30, 2017. “During the quarter, we continued to aggressively drive the clinical program for SRA737, expanding the number of sites recruiting patients into our Monotherapy trial from three to eight lead..."
08/10/2017 8-K Quarterly results
Docs: "Sierra Oncology Reports Second Quarter 2017 Results"
05/09/2017 8-K Form 8-K - Current report
11/10/2016 8-K Form 8-K - Current report
08/12/2016 8-K Form 8-K - Current report
05/10/2016 8-K Form 8-K - Current report
11/05/2015 8-K Quarterly results
Docs: "ProNAi Therapeutics Reports Third Quarter 2015 Results Vancouver - Nov 5, 2015. ProNAi Therapeutics, Inc. , a clinical-stage oncology company pioneering a novel class of therapeutics based on its proprietary DNAi technology platform, today reported its financial and operational results for the third quarter of 2015. “We recently announced the initiation of Brighton, a Phase 2 monotherapy trial evaluating our lead DNAi-based product candidate PNT2258 in approximately 50 patients with Richter's transformation, a rare form of lymphoma with no approved treatments. We also continue to enroll patients in Wolverine, our Phase 2 monotherapy trial of PNT2258 in patients with relapsed or refractory diffuse large B-cell lymphoma, DLBCL, and we remain on track to report initial data from this trial in..."
08/21/2015 8-K Quarterly results
Docs: "ProNAi Therapeutics Reports Second Quarter 2015 Results Completed Upsized Initial Public Offering, Raising Gross Proceeds of $158.4 Million Advanced Clinical Programs for PNT2258 in DLBCL and Richter's Transformed CLL Strengthened Management Team and Board of Directors Vancouver - Aug 21, 2015. ProNAi Therapeutics, Inc. , a clinical-stage oncology company pioneering a novel class of therapeutics based on its proprietary DNAi technology platform, today reported its financial and operational results for the second quarter of 2015. “During the second quarter we continued to advance our clinical programs for PNT2258, opening clinical trial sites and enrolling patients into our Phase 2 Wolverine trial in DLBCL, while preparing for the initiation of our registration-oriented Phase 2 Brighton tri..."

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy